Patents by Inventor Sandra De Meyer
Sandra De Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140127797Abstract: The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.Type: ApplicationFiled: August 21, 2013Publication date: May 8, 2014Applicant: JANSSEN R&D IRELANDInventors: INGE DIERYNCK, SANDRA DE MEYER
-
Patent number: 8592161Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: December 20, 2006Date of Patent: November 26, 2013Assignee: Janssen R&D IrelandInventors: Sandra De Meyer, Hilde Azijn, Marie-Pierre T. M. M. G. De Bethune
-
Patent number: 8557854Abstract: A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention.Type: GrantFiled: April 14, 2006Date of Patent: October 15, 2013Assignee: Janssen R&D IrelandInventors: Gerben Albert Van 'T Klooster, Piet Tom Bert Paul Wigerinck, Sandra De Meyer, Lieven Elvire Colette Baert, Herman Augustinus De Kock
-
Patent number: 8546076Abstract: The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.Type: GrantFiled: June 21, 2012Date of Patent: October 1, 2013Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Inge Dierynck, Sandra De Meyer
-
Publication number: 20120258448Abstract: The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.Type: ApplicationFiled: June 21, 2012Publication date: October 11, 2012Inventors: Inge DIERYNCK, Sandra DE MEYER
-
Publication number: 20110166061Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: April 26, 2010Publication date: July 7, 2011Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra De Meyer
-
Publication number: 20100173282Abstract: The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e. correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.Type: ApplicationFiled: May 23, 2008Publication date: July 8, 2010Applicant: TIBOTEC PHARMACEUTICALS LTD.Inventors: Inge Dierynck, Sandra De Meyer
-
Publication number: 20080287488Abstract: A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention.Type: ApplicationFiled: April 14, 2006Publication date: November 20, 2008Applicant: Tibotec Pharmaceuticals Ltd.Inventors: Gerben Albert Eleutherius Van 'T Klooster, Piet Tom Bert Paul Wigerinck, Sandra De Meyer, Lieven Elvire Colette Baert, Herman Augustinus De Kock
-
Patent number: 7429677Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: GrantFiled: March 11, 2003Date of Patent: September 30, 2008Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Marie-Pierre T. M. M. G De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Jian Lu, Lieve Emma Jan Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat
-
Patent number: 7217506Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: June 30, 2003Date of Patent: May 15, 2007Inventors: Sandra De Meyer, Hilde Azijn, Marie-Pierre T. M. M. G De Bethune
-
Publication number: 20060025594Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: ApplicationFiled: March 11, 2003Publication date: February 2, 2006Applicant: TIBOTEC Pharmaceuticals Ltd.Inventors: Marie-Pierre De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Lu, Lieve Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat
-
Publication number: 20050233312Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: June 30, 2003Publication date: October 20, 2005Inventors: Sandra De Meyer, Hilde Azijn, Marie-Pierre De Bethune